Product logins

Find logins to all Clarivate products below.


Unmet Need in Glioblastoma: Can Emerging Immunotherapies Provide the Answer?

Immunotherapy is one of the most exciting areas of oncology drug development. Numerous manufacturers and investors are entering the field and are rapidly expanding and diversifying their portfolios. Given the great unmet need in glioblastoma for therapies able to extend OS, immunotherapy, including novel vaccines and immune checkpoint inhibitors, could provide a valuable treatment option for glioblastoma patients who do not respond to or experience a recurrence of their disease following conventional therapy.

Related Market Assessment Reports

Report
Cystic Fibrosis – Unmet Need – Unmet Need – Cystic Fibrosis (US EU)
Cystic fibrosis (CF) is a genetic disease associated with more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. These mutations cause aberrant…
Report
Myasthenia Gravis – Unmet Need – Unmet Need – Generalized Myasthenia Gravis (US/EU)
Myasthenia gravis (MG) is a rare autoimmune disorder in which antibodies impair acetylcholinemediated neuromuscular transmission, causing fluctuating muscle weakness. Generalized MG (gMG) often…
Report
Axial Spondyloarthritis – Unmet Need – Unmet Need – Ankylosing Spondylitis (US/EU)
Over the past two decades, TNF-α inhibitors (AbbVie’s Humira, Amgen / Pfizer’s Enbrel, Johnson & Johnson Innovative Medicine’s Remicade and Simponi, and UCB’s Cimzia) have significantly…
Report
Schizophrenia – Unmet Need – Unmet Need – Negative Symptoms of Schizophrenia (US/EU)
Negative symptoms of schizophrenia—often occurring along with positive symptoms—include diminished emotional expression (affective flattening), reduced goal-directed behavior (avolition),…
Report
Paroxysmal Nocturnal Hemoglobinuria – Unmet Need – Unmet Need – Paroxysomal Nocturnal Hemoglobinuria (US/EU)
The treatment landscape for paroxysmal nocturnal hemoglobinuria (PNH) has shifted dramatically in the past decade, moving beyond supportive care to transformative complement inhibition therapies…